Quentin de Hemptinne1, Myriam Remmelink2, Serge Brimioulle1, Isabelle Salmon2, Jean-Louis Vincent3. 1. Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 2. Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 3. Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: jlvincen@ulb.ac.be.
Abstract
BACKGROUND: The heterogeneity of populations meeting criteria for ARDS may explain in part why no specific treatment has yet been shown to decrease mortality. To define the pathologic alterations associated with the syndrome, particularly the typical pattern of diffuse alveolar damage (DAD), and to evaluate whether etiologies or precipitating factors were missed, we evaluated patients who died with a clinical diagnosis of ARDS and who had a postmortem examination. METHODS: We conducted a 3-year (2002 to 2004) review of all patients with ARDS (using the American-European Consensus Conference criteria) who died in our ICU and had a postmortem examination. Discrepancies between antemortem and postmortem diagnoses were classified as major and minor using the Goldman classification. RESULTS: Of 9,184 hospital admissions, 376 patients had a clinical diagnosis of ARDS. Of these, 169 died; 69 had a postmortem examination, and 64 of these had complete data for analysis. The main cause of death was multiple organ failure (27 of 64 patients). Postmortem examination revealed DAD in 32 patients (50%), pneumonia without DAD in 16 patients (25%), and invasive pulmonary aspergillosis in 8 patients (12.5%). Major unexpected findings were found in 15 patients (23%): 7 Goldman class I (including 4 cases of invasive pulmonary aspergillosis and 1 of disseminated tuberculosis) and 8 Goldman class II. CONCLUSIONS: In this study, ARDS remains a heterogeneous syndrome because only half of patients with ARDS had typical DAD. Open lung biopsy, if performed, might have led to appropriate therapy and potentially better outcome in five of the patients.
BACKGROUND: The heterogeneity of populations meeting criteria for ARDS may explain in part why no specific treatment has yet been shown to decrease mortality. To define the pathologic alterations associated with the syndrome, particularly the typical pattern of diffuse alveolar damage (DAD), and to evaluate whether etiologies or precipitating factors were missed, we evaluated patients who died with a clinical diagnosis of ARDS and who had a postmortem examination. METHODS: We conducted a 3-year (2002 to 2004) review of all patients with ARDS (using the American-European Consensus Conference criteria) who died in our ICU and had a postmortem examination. Discrepancies between antemortem and postmortem diagnoses were classified as major and minor using the Goldman classification. RESULTS: Of 9,184 hospital admissions, 376 patients had a clinical diagnosis of ARDS. Of these, 169 died; 69 had a postmortem examination, and 64 of these had complete data for analysis. The main cause of death was multiple organ failure (27 of 64 patients). Postmortem examination revealed DAD in 32 patients (50%), pneumonia without DAD in 16 patients (25%), and invasive pulmonary aspergillosis in 8 patients (12.5%). Major unexpected findings were found in 15 patients (23%): 7 Goldman class I (including 4 cases of invasive pulmonary aspergillosis and 1 of disseminated tuberculosis) and 8 Goldman class II. CONCLUSIONS: In this study, ARDS remains a heterogeneous syndrome because only half of patients with ARDS had typical DAD. Open lung biopsy, if performed, might have led to appropriate therapy and potentially better outcome in five of the patients.
Authors: Nuala J Meyer; Mingyao Li; Rui Feng; Jonathan Bradfield; Robert Gallop; Scarlett Bellamy; Barry D Fuchs; Paul N Lanken; Steven M Albelda; Melanie Rushefski; Richard Aplenc; Helen Abramova; Elena N Atochina-Vasserman; Michael F Beers; Carolyn S Calfee; Mitchell J Cohen; Jean-Francois Pittet; David C Christiani; Grant E O'Keefe; Lorraine B Ware; Addison K May; Mark M Wurfel; Hakon Hakonarson; Jason D Christie Journal: Am J Respir Crit Care Med Date: 2011-01-21 Impact factor: 21.405
Authors: José A Lorente; Pablo Cardinal-Fernández; Diego Muñoz; Fernando Frutos-Vivar; Arnaud W Thille; Carlos Jaramillo; Aida Ballén-Barragán; José M Rodríguez; Oscar Peñuelas; Guillermo Ortiz; José Blanco; Bruno Valle Pinheiro; Nicolás Nin; María del Carmen Marin; Andrés Esteban; Taylor B Thompson Journal: Intensive Care Med Date: 2015-09-18 Impact factor: 17.440
Authors: Daniele De Luca; Marco Piastra; Giovanna Chidini; Pierre Tissieres; Edoardo Calderini; Sandrine Essouri; Alberto Medina Villanueva; Ana Vivanco Allende; Marti Pons-Odena; Luis Perez-Baena; Michael Hermon; Ascanio Tridente; Giorgio Conti; Massimo Antonelli; Martin Kneyber Journal: Intensive Care Med Date: 2013-10-08 Impact factor: 17.440